Iron deprivation and cancer: A view beginning with studies of monoclonal antibodies against the transferrin receptor

Histology and Histopathology

Volumn 12, Issue 1, 1997, Pages 291-296

  Kemp, J D ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

cancer treatment; deferoxamine; gallium; iron; monoclonal antibodies; transferrin receptor

Indexed keywords

DEFEROXAMINE; GALLIUM NITRATE; IRON; MONOCLONAL ANTIBODY; TRANSFERRIN RECEPTOR;

CANCER; HUMAN; HUMAN CELL; LYMPHOMA CELL LINE; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DEFEROXAMINE; GALLIUM; HUMANS; IRON; MICE; NEOPLASMS, EXPERIMENTAL; RECEPTORS, TRANSFERRIN; SIDEROPHORES;

MURINAE;

EID: 0031024826     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (3)

1. Atkin C.L., Thelander L., Reichard P. and Lang G. (1973). Iron and free radical in ribonucleotide reductase. Exchange of iron and Mossbauer spectroscopy of the protein B2 subunit of the Escherichia coli enzyme. J. Biol. Chem. 248, 7464.
2. Bergman Y. and Haimovich J. (1977). Characterization of a carcinogen-induced murine B lymphocyte cell line of C3H/eb origin. Eur. J. Immunol. 7, 413-417.
3. Wright T.L. and Lake J.R. (1990). Mechanisms of transport of nontransferrin-bound iron in basolateral and canalicular rat liver plasma membrane vesicles. Hepatology 12, 498-504.